DNL747
As of the edition of 20 October 2026, DNL747 is a drug known only by a code name: stopped in 2020; acts on RIPK1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Code name only
- Registered trials
- 2, 1 stopped early
- Disease areas
- Nervous system; Mental health; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of DNL747.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| RIPK1 | Receptor-interacting serine/threonine-protein kinase 1 | Q13546 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sanofi | Lead sponsor of trials | 2018 to now |
| Denali Therapeutics | Lead sponsor of trials | 2019 to now |